The emerging role of anti-angiogenic therapy in ovarian cancer (review)

International Journal of Oncology

Volumn 44, Issue 5, 2014, Pages 1417-1424

  Conteduca, Vincenza ^a   Kopf, Barbara ^b   Burgio, Salvatore Luca ^a   Bianchi, Emanuela ^a   Amadori, Dino ^a   De Giorgi, Ugo ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

Angiogenesis; Bevacizumab; Chemotherapy; Epithelial ovarian cancer; Monoclonal antibody; Tyrosine kinase inhibitor; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CABOZANTINIB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MICRORNA; MONOCLONAL ANTIBODY; NINTEDANIB; PACLITAXEL; PAZOPANIB; PERTUZUMAB; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TOPOTECAN; TRASTUZUMAB; TREBANANIB; VOLOCIXIMAB;

ADD ON THERAPY; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNE SYSTEM; LOW DRUG DOSE; MAINTENANCE THERAPY; MOLECULAR BIOLOGY; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEM CELL; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; OVARIAN NEOPLASMS; PROTEIN-TYROSINE KINASES;

EID: 84899096671     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2334     Document Type: Review

References (83)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Jelovac D and Armstrong DK: Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 61: 183-203, 2011.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008. (Pubitemid 351521864)
4. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, et al: SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2010/, based on November 2012 SEER data submission, posted to the SEER web site, 2013.
5. Folkman J: Tumor angiogenesis. Therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
6. Conway E-M, Collen D and Carmeliet P: Molecular mechanisms of blood vessel growth. Cardiovasc Res 49: 507-521, 2001. (Pubitemid 32146414)
7. Chavakis E and Dimmeler S: Regulation of endothelial cell survival and apoptosis during angiogenesis. Arterioscler Thromb Vasc Biol 22: 887-893, 2002. (Pubitemid 34655213)
8. Van der Bilt AR, de Vries EG, de Jong S, Timmer-Bosscha H, van der Zee AG and Reyners AK: Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer. Crit Rev Oncol Hematol 84: 224-242, 2012.
9. Claesson-Welsh L and Welsh M: VEGFA and tumour angiogenesis. J Intern Med 273: 114-127, 2013.
10. Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L: VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371, 2006.
11. Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027, 2005. (Pubitemid 46202320)
12. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vinent L, Costa C, MacDonald DD, et al: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 6: 820-827, 2005. (Pubitemid 41753060)
13. Lichtenberger BM, Tan PK, Niederleithner H, Ferrara N, Petzelbauer P and Sibilia M: Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 6: 268-279, 2010.
14. Trinh XB, Tjalma WA, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, Helleman J, et al: The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer 100: 971-978, 2009.
15. Zhang A, Meng L, Wang Q, Chen G, Wang S, Zhou J, Lu Y, et al: Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2. Oncol Rep 15: 831-836, 2006.
16. Artini PG, Ruggiero M, Monteleone P, Carpi A, Cristello F, Cela V, Genazzani AR, et al: Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors. Biomed Pharmacother 62: 373-377, 2008. (Pubitemid 351899098)
17. Lawicki S, Bȩdkowska GE, Gacuta-Szumarska E and Szmitkowski M: The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. J Ovarian Res 6: 45, 2013.
18. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, et al: Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10: 3291-3300, 2004.
19. Li L, Wang L, Zhang W, Tang B, Zhang J, Song H, Yao D, et al: Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res 24: 1973-1979, 2004. (Pubitemid 38954620)
20. Rudlowski C, Pickart AK, Fuhljahn C, Friepoertner T, Schlehe B, Biesterfeld S and Schroeder W: Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer 16: 183-189, 2006.
21. Yu L, Deng L, Li J, Zhang Y and Hu L: The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol 128: 391-396, 2013.
22. Hu L, Hoffmann J, Zaloudak C, Ferrara N, Hamilton T and Jaffe RB: Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161: 1917-1924, 2002. (Pubitemid 35265548)
23. Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos GD, et al: Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9: 5721-5728, 2003. (Pubitemid 37499496)
24. Tran J, Master Z, Yu JL, Rak J, Dumont DJ and Kerbel RS: A role of surviving in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 99: 4349-4354, 2002. (Pubitemid 34285988)
25. Martin L and Schilder R: Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol 25: 2894-2901, 2007. (Pubitemid 47123153)
26. Osada R, Horiuchi A, Kikuchi N, Ohira S, Ota M, Katsuyama Y and Konishi I: Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. Hum Pathol 37: 1414-1425, 2006. (Pubitemid 44584330)
27. Fu Y, Lai Y, Wang Q, Liu X, He W, Zhang H, Fan C, et al: Overexpression of clusterin promotes angiogenesis via the vascular endothelial growth factor in primary ovarian cancer. Mol Med Rep 7: 1726-1732, 2013.
28. Eckhoff K, Flurschütz R, Trillsch F, Mahner S, Jänicke F and Milde-Langosch K: The prognostic significance of Jun transcription factors in ovarian cancer. J Cancer Res Clin Oncol 139: 1673-1680, 2013.
29. Mahner S, Baasch C, Schwarz J, Hein S, Wölber L, Jänicke F and Milde-Langosch K: C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer 99: 1269-1275, 2008.
30. Kusumbe AP, Mali AM and Bapat SA: CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature. Stem Cells 27: 498-508, 2009.
31. Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, et al: Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer 130: 29-39, 2012.
32. Burgos-Ojeda D, Rueda BR and Buckanovich RJ: Ovarian cancer stem cell markers: Prognostic and therapeutic implications. Cancer Lett 322: 1-7, 2012.
33. Alvero AB, Fu HH, Holmberg J, Visintin I, Mor L, Marquina CC, Oldtman J, et al: Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 27: 2405-2413, 2009.
34. Liang D, Ma Y, Liu J, Trope CG, Holm R, Nesland JM and Suo Z: The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer 12: 201, 2012.
35. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB and Rich JN: Hypoxia inducible factors in cancer stem cells. Br J Cancer 102: 789-795, 2010.
36. Yin G, Alvero AB, Craveiro V, Holmberg JC, Fu HH, Montagna MK, Yang Y, et al: Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene 32: 39-49, 2012.
37. Cao L, Shao M, Schilder J, Guise T, Mohammad KS and Matei D: Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene 31: 2521-2534, 2012.
38. Jiao J, Huang L, Ye F, Shi M, Cheng X, Wang X, Hu D, et al: Cyclin D1 affects epithelial-mesenchymal transition in epithelial ovarian cancer stem cell-like cells. Onco Targets Ther 6: 667-677, 2013.
39. Yang H and Chen B: CD147 in ovarian and other cancers. Int J Gynecol Cancer 23: 2-8, 2013.
40. Yang H, Zou W and Chen B: Overexpression of CD147 in ovarian cancer is initiated by the hypoxic microenvironment. Cell Biol Int 37: 1139-1142, 2013.
41. Millimaggi D, Mari M, D'Ascenzo S, Carosa E, Jannini EA, Zucker S, Carta G, et al: Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia 9: 349-357, 2007. (Pubitemid 46608302)
42. Zaffryar-Eilot S, Marshall D, Voloshin T, Bar-Zion A, Spangler R, Kessler O, Ghermazien H, et al: Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours. Carcinogenesis 34: 2370-2379, 2013.
43. Su Y, Gao L, Teng L, Wang Y, Cui J, Peng S and Fu S: Id1 enhances human ovarian cancer endothelial progenitor cell angiogenesis via PI3K/Akt and NF-κB/MMP-2 signaling pathways. J Transl Med 11: 132, 2013.
44. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, et al: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14: 2690-2695, 2008.
45. He J, Jing Y, Li W, Qian X, Xu Q, Li FS, Liu LZ, et al: Roles and mechanism of miR-199a and miR-125b in tumor angiogenesis. PLoS One 8: e56647, 2013.
46. Bamias A, Pignata S and Pujade-Lauraine E: Angiogenesis: A promising therapeutic target for ovarian cancer. Crit Rev Oncol Hematol 84: 314-326, 2012.
47. Ziogas, Gavalas N, Tsiatas M, Tsitsilonis O, Politi E, Terpos E, Rodolakis A, et al: VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2. Int J Cancer 130: 857-864, 2012.
48. Wang X, Zhao X, Wang K, Wu L and Duan T: Interaction of monocytes/macrophages with ovarian cancer cells promotes angiogenesis in vitro. Cancer Sci 104: 516-523, 2013.
49. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG and Modi NB: Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288: 371-378, 1999. (Pubitemid 29113511)
50. Jain R: Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19: 7-16, 2005.
51. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, et al: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: 2473-2483, 2011.
52. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, et al: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365: 2484-2496, 2011.
53. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, et al: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30: 2039-2045, 2012.
54. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, et al: AURELIA: a randomised phase III trial evaluating bevacizumab combined with chemotherapy for platinum resistant recurrent ovarian cancer. J Clin Oncol 30: (abst, LBA5002), 2012.
55. Garcia A, Hirte H, Fleming G, Yang D, Tsao- Wei D, Roman L, Groshen S, et al: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26: 76-82, 2008.
56. McGonigle K, Muntz H, Vuky J, Paley P, Veljovich D, Greer B, Goff BA, et al: Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer 117: 3731-3740, 2011.
57. Kudoh K, Takano M, Kouta H, Kikuchi R, Kita T, Miyamoto M, Watanabe A, et al: Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecol Oncol 122: 233-237, 2011.
58. O'Malley DM, Richardson DL, Rheaume PS, Salani R, Eisenhauer EL, McCann GA, Fowler JM, et al: Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol 121: 269-272, 2011.
59. Verschraegen CF, Czok S, Muller CY, Boyd L, Lee SJ, Rutledge T, Blank S, et al: Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer. Ann Oncol 23: 3104-3110, 2012.
60. Tillmanns TD, Lowe MP, Walker MS, Stepanski EJ and Schwartzberg LS: Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecol Oncol 128: 221-228, 2013.
61. Del Carmen MG, Micha J, Small L, Street DG, Londhe A and McGowan T: A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol 126: 369-374, 2012.
62. Burger R, Sill M, Monk B, Greer B and Sorosky J: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 25: 5165-5171, 2007. (Pubitemid 350237599)
63. Cannistra S, Matulonis U, Penson R, Hambleton J, Dupont J, Mackey H, Douglas J, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25: 5180-5186, 2007. (Pubitemid 350232248)
64. Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R, et al: Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 110: 49-55, 2008.
65. Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, et al: Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res 16: 5320-5328, 2010.
66. Morgan R, Oza AM, Qin R, Laumann KM, Mackay H, Strevel EL, Welch S, et al: A phase II trial of temsirolimus and bevacizumab in patients with endometrial, ovarian, hepatocellular carcinoma, carcinoid, or islet cell cancer: ovarian cancer (OC) subset - a study of the Princess Margaret, Mayo, Southeast phase II, and California Cancer (CCCP) N01 Consortia NCI#8233. J Clin Oncol 29: 5015, 2011.
67. Kohn EC, Lee J, Annunziata CM, Minasian LM, Zujewski J, Prindiville SA, Kotz HL, et al: A phase II study of intermittent sorafenib with bevacizumab in bevacizumab-naive epithelial ovarian cancer (EOC) patients. J Clin Oncol 29: 5019, 2011.
68. Tew WP, Colombo N, Ray-Coquard I, Oza A, del Campo J, Scambia G and Spriggs D: VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study. J Clin Oncol 25: 5508, 2007.
69. Colombo N, Mangili G, Mammoliti S, Kalling M, Tholander B, Sternas L, Buzenet G, et al: A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol 125: 42-47, 2012.
70. Friedlander M, Hancock KC, Rischin D, Ma B, et al: A phase II open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 119: 32-37, 2010.
71. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, et al: Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27: 5601-5606, 2009.
72. Biagi JJ, Oza AM, ChalCha HI, Grimshaw R, Ellard SL, Lee U, Hirte H, et al: A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 22: 335-340, 2011.
73. Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, Yamada SD, et al: Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 29: 69-75, 2011.
74. Welch SA, Hirte WHMD, Elit L, Schilder RJ, Wang L, Macalpine K, Wright JJ, et al: Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer. A study of the Princess Margaret Hospital Phase II Consortium. Int J Gynecol Cancer 20: 787-793, 2010.
75. Pölcher M, Eckhardt M, Coch C, Wolfgarten M, Kübler K, Hartmann G, Kuhn W, et al: Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol 66: 203-207, 2010.
76. Matei D, Ramasubbaiah R, Schilder J, Perkins S, Whalen C, Breen T, Johnson CS, et al: A phase I/II study of topotecan and sorafenib in recurrent, platinum-resistant ovarian cancer: HOG GYN-111. J Clin Oncol 28: 5108, 2010.
77. Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, Earl H, et al: Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 29: 3798-3804, 2011.
78. Buckanovich RJ, Berger R, Sella A, Sikic BI, Shen X, Ramies DA, Smith DC, et al: Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 29: 5008, 2011.
79. Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, Miner Z, et al: Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. J Clin Oncol 26: 3418-3425, 2008.
80. Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, Chambers SK, et al: Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30: 362-371, 2012.
81. Downs Jr LS, Judson PL, Argenta PA, Ghebre R, Geller MA, Bliss RL, Boente MP, et al: A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer 112: 331-339, 2008.
82. Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, Ivanov I, et al: Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol 119: 444-450, 2010.
83. Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, LengYel E, et al: A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 121: 273-279, 2011.